title: Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension.
abstract: The efficacy of cilazapril monotherapy was evaluated in 2 multicentre double-blind dose-response trials. After 4 weeks of a single-blind placebo run-in period, patients with uncomplicated mild to moderate essential hypertension and a sitting diastolic blood pressure of 100 to 115 mm Hg, 24 hours after the last placebo dose (trough), were randomised to take either placebo or cilazapril 2.5 mg or 5 mg for 4 weeks (study 1, 86 patients) or 8 weeks (study 2, 78 patients). Sitting diastolic blood pressure was checked every 2 weeks at trough in both studies and at peak in study 2. The reductions in sitting diastolic blood pressure from baseline at trough, and the difference from placebo, were clinically and statistically significant for both cilazapril groups in the 2 studies. The reduction in blood pressure in both active treatment groups was similar, but the response rate with cilazapril 5 mg was greater than that with 2.5 mg. More than 50% of the peak effect was still present at trough for both cilazapril groups. It is concluded that both dosages of cilazapril are effective and reduce blood pressure compared with placebo over a 24-hour period.
authors.affiliation: Hadassah University Hospital, Jerusalem, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Kobrin
authors.forename: P
authors.initials: P
authors.lastname: Güntzel
authors.forename: R
authors.initials: R
authors.lastname: Viskoper
authors.forename: E
authors.initials: E
authors.lastname: Paran
authors.forename: R
authors.initials: R
authors.lastname: Zimlichman
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D017315:Cilazapril; D003971:Diastole / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011187:Posture / Q000502:physiology; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D011724:Pyridazines; D017315:Cilazapril